SHENYANG, China, March 4, 2016 /PRNewswire/ -- 3SBio Inc. (Hong Kong: 1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce that Kevin Xiao Weihong has joined 3SBio as its new chief operating officer.
"We are pleased to welcome Kevin to 3SBio where he will play a key role in providing leadership for the 3SBio Group's 1,800 sales and marketing professionals as we have extended our successful nephrology and oncology commercial platform to include rheumatology and dermatology, and broad market availability to meet China's demand for safe, effective and affordable medicines," Dr. Jing Lou, Chairman and CEO of 3SBio commented.
"I'm very excited to be joining a world class team and contributing to the next stage of 3SBio's development," commented Mr. Xiao.
Mr. Xiao has extensive experience within PRC's pharmaceutical industry. He served as chief executive officer of Hisun Pfizer Pharmaceutical Co. Ltd. from 2012 to 2015 where he oversaw the strategy and operations of the Hisun and Pfizer joint venture. From 2007 to 2012, Mr. Xiao served as a general manager of Commercial and Diversified Business BU of Pfizer China. Prior to this role Mr. Xiao worked in Pfizer China's human resources department from 1999 to 2007 and served as HR Director of Pfizer China from 2004 to 2007. Mr. Xiao graduated from the University of International Business & Economics with a Bachelor of Economics degree in 1991. He is currently the vice president of the Chinese Pharmaceutical Enterprises Association.
After his appointment as chief operating officer, Mr. Xiao will work closely with the management of 3SBio in the day-to-day management of the 3SBio Group and will work under the immediate authority of and report directly to Dr. Jing Lou, Chairman and CEO of 3SBio.
About 3SBio
3SBio is a leading biotechnology company in the People's Republic of China (the "PRC") founded in 1993. As a pioneer in the PRC biotechnology industry, 3SBio has extensive expertise in developing, manufacturing and marketing biopharmaceuticals. Three core products, TPIAO, Yisaipu and EPIAO are market leaders in the PRC. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world. Yisaipu, a monoclonal antibody developed by Shanghai CP Guojian Pharmaceutical Co., Ltd. ("Guojian"), one of 3SBio's subsidiaries, for the treatment of rheumatoid arthritis is the industry leader with a market share in excess of 60% according to IMS data. EPIAO, a recombinant human erythropoietin (rhEPO) product, together with the other rhEPO product acquired recently, SEPO, is the dominant market leader in the rhEPOmarket, with a market share more than the combined market shares of the next five largest competitors, according to IMS data. In addition, 3SBio has more than 50 other products in the nephrology, oncology, rheumatology, dermatology and other therapeutic areas. 3SBio is focused on building an innovative product pipeline, with over 20 National Class 1 candidates under development.
3SBio maintains operation facilities in Shenyang, Benxi, Shanghai, Hangzhou and Shenzhen, as well as in Como, Italy, with a total of over 3,000 employees. A state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards. In July 2015, 3SBio acquired Zhejiang Wansheng Pharmaceutical Co., Ltd., which specializes in R&D, production and sales of chemically synthesized pharmaceuticals. In November 2015, 3SBio acquired a controlling interest in Guojian, a leading company in China's antibody sector that develops and commercializes new biologic therapies targeting cancer, autoimmune diseases and organ transplantation immunosuppression treatment. Guojian's antibody manufacturing capacity is among the largest in the industry.
3SBio's pharmaceutical products are marketed and sold in 32 provinces, autonomous regions and special municipalities in the PRC, as well as a number of foreign countries and regions. 3SBio's nationwide sales and distribution network covers over 3,400 hospitals and medical institutions in the PRC. 3SBio is also actively pursuing international expansion through acquisition, licensing and partnerships.
Please visit www.3sbio.com for additional information.
Contacts
Tom Folinsbee
Director, Corporate Development
3SBio Inc.
Suite 3529 35/F Central Plaza
18 Harbour Road, Wanchai
Hong Kong
Tel: +852 2593-1243
Email: tomfolinsbee@3sbio.com
Rachel You
Financial Controller
3SBio Inc.
Suite 3529 35/F Central Plaza
18 Harbour Road, Wanchai
Hong Kong
Tel: +852 2593-1243
Email: youfei@3sbio.com
